Curcumin vs Quercetin: Which Is Better for Inflammation?
Should I take curcumin or quercetin?
Different jobs, same shelf. Quercetin scores 6.8 and curcumin 6.5, which decides nothing. Curcumin wins joints, inflammatory markers, gut and mood. Quercetin wins allergies, blood pressure, uric acid and immune function. Both are barely absorbed unless you buy an enhanced form, and both are oversold for longevity.
- Quercetin 6.8, curcumin 6.5. The gap is safety and side effects, not effect: curcumin scores 2.7 on safety risk against quercetin's 1.8.
- Buy curcumin for joints. Feng 2022 found curcuminoids non-inferior to NSAIDs in knee osteoarthritis, and Shep 2019 matched diclofenac with better tolerability.
- Buy quercetin for allergies. Yamada 2022 gave 66 people quercetin phytosome 200 mg a day for 4 weeks and improved eye itching, sneezing, discharge and sleep.
- Only one of them lowers inflammatory markers. Naghsh 2023 found a CRP effect size around 0.74 across more than 5,800 people for curcumin. Ou 2020 found no overall CRP, IL-6 or TNF effect for quercetin.
- Both are barely absorbed as the cheap version. Quercetin phytosome reaches about 20 times the plasma of plain dihydrate (Riva 2019).
- The senolytic story is not proven for quercetin alone. Farr 2024 was null on bone turnover in 60 postmenopausal women and Nambiar 2023 found no efficacy signal.
- Curcumin has a real liver signal. The DILIN series (Halegoua-DeMarzio 2023) reported 10 cases and one death, with an HLA-B*35:01 association.
- They overlap at NF-kB and Nrf2, so stacking them duplicates the shared mechanism and adds two separate bleeding cautions.
At a Glance
Curcumin
- Efficacy 3.5
- Breadth 4.0
- Evidence 3.5
- Speed 2.5
- Durability 2.5
- Bioindividuality 3.0
- Safety Risk 2.7
- Side Effects 2.0
- Cost 1.8
- Effort 1.5
- Opportunity Cost 1.5
- Dependency 1.0
- Reversibility 1.2
- Bone Joint
- Anti Inflammatory
- Chronic Pain
- Gut Health
Turmeric polyphenol, NF-kB and COX-2 inhibitor. BioHarmony 6.5, worth trying.
Quercetin
- Efficacy 3.2
- Breadth 3.8
- Evidence 3.6
- Speed 3.0
- Durability 2.2
- Bioindividuality 3.6
- Safety Risk 1.8
- Side Effects 1.7
- Cost 2.2
- Effort 1.6
- Opportunity Cost 2.5
- Dependency 1.2
- Reversibility 1.6
- Cardiovascular
- Cellular Senescence
- Anti Inflammatory
- Respiratory
Flavonoid, mast cell stabiliser and xanthine oxidase inhibitor. BioHarmony 6.8, worth trying.
Head-to-Head Verdict
| Use Case | Winner | Rationale |
|---|---|---|
| Bone Joint | Curcumin | Curcumin 6.8 against quercetin's 4.2, the widest gap on the board and the single best-evidenced use on this page. Feng 2022 found curcuminoids relieved knee osteoarthritis pain and dysfunction with a WOMAC total improvement around 7 points, non-inferior to NSAIDs.Shep 2019 compared it directly against diclofenac with comparable pain relief and better tolerability. Zhao 2024 pooled 2,175 patients for a visual analogue pain drop of about 1.6 points. |
| Anti Inflammatory | Curcumin | Curcumin 6.3 against 5.0, and the difference is whether a measured marker moves. Naghsh 2023 is an umbrella meta-analysis with a C-reactive protein effect size around 0.74 across more than 5,800 participants, building on Sahebkar 2014.Ou 2020 pooled human quercetin inflammation trials and found no overall effect on CRP, IL-6 or TNF, with subgroup signals only. If lowering CRP is the goal, this row is decisive. |
| Depression | Curcumin | Curcumin 5.0 against quercetin's 1.4. Ng 2017 pooled 377 participants for a Hamilton depression standardised mean difference around 0.34, and Al-Karawi 2016 confirms a modest antidepressant effect. That is a small effect from a supplement, not a treatment. Quercetin has nothing here and its own report scores it accordingly. |
| Gut Health | Curcumin | Curcumin 5.5 against 3.2. The specific evidence is ulcerative colitis as an add-on to mesalamine: a 2018 meta-analysis reported a remission odds ratio of 6.78 across 142 patients. That is an adjunct under gastroenterology supervision rather than a general gut supplement, and it is a real clinical result quercetin cannot match. |
| Respiratory | Quercetin | Quercetin 5.0 against curcumin's 2.5, and this is quercetin's home ground. Yamada 2022 randomised 66 people to quercetin phytosome 200 mg a day for 4 weeks and improved eye itching, sneezing, nasal discharge and sleep disturbance. The mechanism is mast cell stabilisation and histamine release inhibition, which is a specific allergic pathway rather than general anti-inflammation. |
| Cardiovascular | Quercetin | Quercetin 5.8 against 4.6, on the most replicated blood pressure signal here. Serban 2016 pooled 7 RCTs in 587 people for systolic down 3.04 mmHg and diastolic down 2.63, strongest at 500 mg a day or higher, and Popiolek-Kalisz 2022 confirms small effects. Read the size honestly: 3 mmHg is a real but minor shift, and Dower 2015 was null on flow-mediated dilation and blood pressure at 160 mg a day. |
| Immune Function | Quercetin | Quercetin 4.8 against curcumin's 3.2, mostly through the allergy and respiratory route rather than through infection resistance. The honest counterweight is in its own report: Nieman 2010 randomised 1,002 community participants for upper respiratory tract infection with no overall benefit, and only a subgroup signal in fit adults over 40. |
| Cellular Senescence | Quercetin | Quercetin 5.3 against 2.2, and the marketing is far ahead of the data. Quercetin appears in senolytic research as half of dasatinib plus quercetin, not on its own. Hickson 2019 reduced senescence markers in 9 diabetic kidney disease patients in 11 days, and Justice 2019 showed physical function gains in 14 people with pulmonary fibrosis.Then Farr 2024 was null on bone turnover in 60 postmenopausal women and Nambiar 2023 found no frailty or pulmonary function signal. Quercetin alone is not a proven senolytic. |
| Liver Detox | Tie | Curcumin 4.2, quercetin 4.0. Effectively even, and the tie hides a safety asymmetry worth knowing. Curcumin has the better liver efficacy signal, with Wei 2019 showing improved liver enzymes and triglycerides in NAFLD. It also carries the only idiosyncratic liver injury signal on this page: LiverTox gives turmeric a likelihood score A, and the DILIN series documented 10 cases with one death. |
Cost Comparison
| Intervention | Monthly Cost | Notes |
|---|---|---|
| Curcumin | $15 to $40 | Extracted from the source report rather than estimated, priced 2026-09-08, retail. That is the enhanced-absorption price band at 500 mg of curcuminoids: phytosome, piperine or micellar. Plain curcuminoid capsules are cheaper and are the form Nelson 2017 criticises as poorly absorbed and chemically unstable. |
| Quercetin | $20 to $50 | Extracted from the source report rather than estimated, priced 2026-09-08, retail. That covers phytosome, EMIQ and isoquercetin at study doses, which is where the 200 mg a day allergic rhinitis protocol sits. Plain quercetin dihydrate is cheaper and absorbs about 20 times worse (Riva 2019). |
| The difference | About $5 to $10 a month | Close enough to ignore. Both sit in the same $15 to $50 band and neither price should influence the choice, which is unusual for two supplements marketed against each other.What both prices assume is the enhanced form. Buying either as the cheapest plain powder is the single most common way to run a trial that was never going to work: plain curcumin is barely absorbed and plain quercetin dihydrate reaches roughly a twentieth of the plasma a phytosome does. Formulation is the variable that matters, not brand and not dose. |
When to Switch
These run on very different clocks, which is the most useful practical difference between them. Quercetin shows a first noticeable change in about 3 days with full effect at 4 weeks and a 4-week assessment window, because its best use is an acute allergic symptom you can feel.
Curcumin takes 2 weeks for a first change, has an 8-week assessment window and does not reach full effect until 16 weeks. A two-week curcumin trial tells you nothing.
Pick by the complaint, not by the score. Joint pain, a raised CRP, ulcerative colitis alongside mesalamine, or low mood point to curcumin. Seasonal allergies, prehypertension, raised uric acid, or chronic prostatitis point to quercetin. Neither is a general anti-inflammatory you take because inflammation sounds bad, and the reports are blunt about that.
Switch away from curcumin if you develop any liver symptom, and get liver enzymes checked rather than waiting. LiverTox rates turmeric likelihood score A for idiosyncratic injury and the DILIN series reported 10 cases including one death, with an HLA-B*35:01 association.
Switch away from quercetin if you take a narrow-therapeutic-index drug through CYP3A4 or a statin, since Wu 2012 raised pravastatin exposure 24% through OATP1B1.
Stacking them is the popular move and the least justified one. They share NF-kB inhibition and Nrf2 activation, so the overlap is real rather than complementary, and their distinct mechanisms address problems most people do not have simultaneously.
Both also raise bleeding risk and both list surgery within two weeks as a contraindication, so the stack doubles the one risk that actually lands people in trouble.
Who Should Pick What?
Knee or hand osteoarthritis, wanting an alternative to daily NSAIDs
Curcumin
Bone-joint 6.8 against 4.2, and this is the best-evidenced use on the page. Feng 2022 found curcuminoids non-inferior to NSAIDs and Shep 2019 matched diclofenac with better tolerability. Buy an enhanced-absorption form, give it the full 8 weeks, and expect a modest effect rather than a replacement for a joint that needs surgery.
Seasonal or perennial allergic rhinitis
Quercetin
Respiratory 5.0 against 2.5, and the protocol is specific rather than general: quercetin phytosome 200 mg a day during exposure windows, which is exactly what Yamada 2022 tested in 66 people. It works through mast cell stabilisation, so it is a genuine antihistamine-adjacent mechanism rather than an anti-inflammatory guess.
Elevated C-reactive protein you want to bring down
Curcumin
Anti-inflammatory 6.3 against 5.0, and the marker evidence is one-sided. Naghsh 2023 found a CRP effect size around 0.74 across more than 5,800 participants. Ou 2020 pooled quercetin inflammation trials and found no overall effect on CRP, IL-6 or TNF. If the number on the panel is the target, quercetin is the wrong molecule.
Prehypertension or stage 1 hypertension, alongside diet and exercise
Quercetin
Cardiovascular 5.8 against 4.6. Serban 2016 pooled 7 RCTs in 587 people for 3.04 mmHg systolic and 2.63 diastolic, strongest at 500 mg a day or higher, and Edwards 2007 reduced blood pressure at 730 mg a day over 28 days in stage 1 hypertension. Three millimetres is real and small. Keep the monitoring and the lifestyle work.
Ulcerative colitis already on mesalamine
Curcumin
Gut health 5.5 against 3.2, on a 2018 meta-analysis reporting a remission odds ratio of 6.78 in 142 patients as a mesalamine adjunct. Adjunct is the operative word, under your gastroenterologist rather than instead of your prescription.
Raised uric acid or a gout history
Quercetin
This is quercetin's cleanest niche mechanism: xanthine oxidase inhibition, the same enzyme allopurinol targets. Shi 2016 was a 22-person crossover where 500 mg a day lowered uric acid by 26.5 micromol per litre with no change in glucose or blood pressure. A 4-week trial alongside standard urate-lowering care is a reasonable experiment.
Hoping to clear senescent cells and slow aging
Tie
Neither, and quercetin is the one being oversold. Its senolytic reputation comes from dasatinib plus quercetin trials, and the results are mixed: Hickson 2019 in 9 people and Justice 2019 in 14 were feasibility studies, while Farr 2024 was null on bone turnover in 60 women and Nambiar 2023 found no efficacy signal. Curcumin's longevity subrating is 3.2 with even less behind it.
On warfarin, an antiplatelet, or surgery within two weeks
Tie
Neither. Both list anticoagulant or antiplatelet therapy and imminent surgery as contraindications. Choi 2022 is a warfarin interaction case report for quercetin and Poor 2017 describes the albumin displacement plus CYP2C9 mechanism. Curcumin carries the same bleeding caution plus gallstones and bile-duct obstruction.
Taking a statin or another narrow-therapeutic-index drug
Curcumin
Quercetin is the specific problem here. Wu 2012 measured pravastatin area under the curve rising 24% and peak concentration 31% on 500 mg a day for 14 days through OATP1B1, and quercetin inhibits CYP3A4. Curcumin is not free of interactions either, so check iron-deficiency anemia and active chemotherapy before starting it.
Research Highlights
-
Mechanism Difference
These two overlap more than their marketing suggests and diverge where it counts. Both inhibit NF-kB and activate Nrf2, which is the shared anti-inflammatory and antioxidant backbone. That overlap is why stacking them duplicates work rather than compounding it.Their distinct targets explain the verdict split. Curcumin adds COX-2 and 5-LOX suppression and downregulates TNF-alpha and IL-6, which is the prostaglandin route NSAIDs use and why joints respond. Quercetin adds mast cell stabilisation and histamine release inhibition, xanthine oxidase inhibition and PI3K inhibition, which is why allergies and uric acid respond.
-
Absorption Problem
Both molecules fail as the cheap version, and this is the most common reason a trial of either produces nothing. Riva 2019 was a 12-person crossover showing quercetin phytosome reaches roughly 20 times the plasma concentration of plain dihydrate, and Liu 2025 reviewed human bioavailability through 2024 concluding lipid complexation and glucosylation dominate.Curcumin has the same problem and a harsher critique. Nelson 2017 argues curcumin is a pan-assay interference compound that is chemically unstable and poorly absorbed, which is why the source report tells you to budget for a phytosome, piperine or micellar form rather than the cheapest bottle.
-
Cost Comparison
Curcumin runs $15 to $40 a month for enhanced-absorption forms at 500 mg of curcuminoids. Quercetin runs $20 to $50 for phytosome, EMIQ or isoquercetin at study doses. Both figures are extracted from the source reports rather than estimated, and both priced 2026-09-08.The five to ten dollar gap should not decide anything. What matters is that both bands assume the absorbable form. The cheapest plain versions of either cost less and deliver a fraction of the exposure the trials used, which converts a $20 saving into a wasted 8 weeks.
-
Editorial Verdict
Quercetin scores 6.8 and curcumin 6.5, and that 0.3 difference is safety rather than effect: curcumin scores 2.7 on safety risk against quercetin's 1.8, mostly on the liver signal. The use-case rows split cleanly rather than favouring either.Curcumin takes joints, inflammatory markers, gut and mood. Quercetin takes allergies, blood pressure, uric acid, immune function and the senescence row. Name the complaint and the answer is obvious. Buy neither for general inflammation, because that is the framing both reports say the evidence does not support.
-
Safety Comparison
Quercetin is the safer of the two on paper, scoring 1.8 on safety risk and 1.7 on side effects against curcumin's 2.7 and 2.0. The gap is one specific signal: LiverTox rates turmeric likelihood score A for idiosyncratic liver injury, and the DILIN case series (Halegoua-DeMarzio 2023) documented 10 cases including one death, with an HLA-B*35:01 association.Their exclusion lists share bleeding risk, surgery within two weeks, and active cancer treatment without oncology sign-off. Curcumin adds gallstones and bile-duct obstruction, iron-deficiency anemia because it chelates iron, and active peptic ulcer. Quercetin adds pregnancy and conception attempts, pediatric use outside a clinician protocol, and narrow-therapeutic-index CYP3A4 drugs.
-
What Is Oversold
Both reports name their own marketing problems. A 2025 umbrella review rated most curcumin meta-analyses low or very low certainty on AMSTAR-2 and GRADE, and its cognitive case needs about 0.8 g a day for at least 24 weeks (Wang 2025) rather than the doses people take.Quercetin's oversold claims are senolytic, antiviral, mast cell activation syndrome, cancer and broad longevity. Its own verdict says so. Brandao 2024 lowered ACE2 and TMPRSS2 in cultured lung cells without reducing SARS-CoV-2, Macready 2012 found no meaningful cognitive benefit, and Kressler 2011 pooled 11 exercise studies for a trivial endurance effect of about 2%.
Frequently Asked Questions
- Should I take curcumin or quercetin for inflammation?
- It depends what inflammation means to you. If it is a raised CRP, curcumin: Naghsh 2023 found an effect size around 0.74 across more than 5,800 people, while Ou 2020 found no overall CRP, IL-6 or TNF effect for quercetin. If it is an allergic reaction, quercetin, through mast cell stabilisation. Neither is a general anti-inflammatory worth taking without a target.
- Which is better for joint pain?
- Curcumin, and it is not close. Bone-joint scores 6.8 against 4.2. Feng 2022 found curcuminoids non-inferior to NSAIDs in knee osteoarthritis with a WOMAC improvement around 7 points, and Shep 2019 matched diclofenac with better tolerability. Give it 8 weeks and use an enhanced-absorption form.
- Does quercetin actually clear senescent cells?
- Not on its own, on current evidence. The senolytic research pairs it with dasatinib, a prescription drug. Hickson 2019 and Justice 2019 were tiny feasibility studies with 9 and 14 people, and the better-powered follow-ups went the other way: Farr 2024 was null on bone turnover in 60 women and Nambiar 2023 found no efficacy signal.
- Do I need an expensive form of either one?
- Yes, and this matters more than dose. Riva 2019 found quercetin phytosome reaches about 20 times the plasma of plain dihydrate, and Liu 2025 confirmed lipid complexation and glucosylation dominate absorption. Curcumin has the same issue, with Nelson 2017 arguing it is unstable and poorly absorbed. Budget $15 to $50 a month for the absorbable form or do not bother.
- Can I take curcumin and quercetin together?
- You can, and there is less reason than people assume. They share NF-kB inhibition and Nrf2 activation, so the overlap is duplication rather than synergy, and their distinct mechanisms answer problems most people do not have at once. Both also raise bleeding risk and both list surgery within two weeks as a contraindication, so the stack doubles that specific risk.
- Is curcumin bad for your liver?
- Rarely, and the signal is real rather than theoretical. LiverTox rates turmeric likelihood score A for idiosyncratic liver injury, and the DILIN series reported 10 cases including one death, with an HLA-B*35:01 association. The source report advises avoiding piperine-heavy products long term. If you have liver disease or that genotype, this is a conversation with a clinician.
- How long before either one works?
- Quercetin is fast: first change in about 3 days, full effect at 4 weeks, and a 4-week assessment window. Curcumin is slow: 2 weeks for a first change, an 8-week window, and full effect at 16 weeks. That difference is why a two-week curcumin trial tells you nothing and a two-week quercetin trial tells you most of what you need.
- Does quercetin interact with my medications?
- It can, and statins are the clearest case. Wu 2012 measured pravastatin exposure rising 24% on 500 mg a day for 14 days through OATP1B1, and quercetin inhibits CYP3A4, which is why narrow-therapeutic-index drugs are on its contraindication list. Choi 2022 is a warfarin case report. Curcumin's list is different: anticoagulants, iron-deficiency anemia, gallstones and active chemotherapy.
Evidence Sources
- Meta-analysis Curcuminoids for knee osteoarthritis, non-inferior to NSAIDs (2022) WOMAC total improvement around 7 points. Non-inferior to NSAIDs for pain and dysfunction.
- RCT Curcumin versus diclofenac in knee osteoarthritis (2019) Comparable pain relief with better tolerability than diclofenac.
- Meta-analysis Bayesian network meta-analysis of knee osteoarthritis treatments (2024) 2,175 patients. Visual analogue pain drop of about 1.6 points.
- Meta-analysis Umbrella meta-analysis of curcumin and inflammatory biomarkers (2023) C-reactive protein effect size around 0.74 across more than 5,800 participants.
- Meta-analysis Curcuminoids and C-reactive protein (2014) The original CRP-lowering signal for curcuminoids.
- Meta-analysis Curcumin in depression, meta-analysis (2017) 377 participants. Hamilton depression standardised mean difference around 0.34.
- Meta-analysis Curcumin for ulcerative colitis remission as a mesalamine adjunct (2018) 142 patients. Remission odds ratio 6.78 as an add-on to mesalamine.
- Meta-analysis Curcumin and NAFLD metabolic parameters (2019) Liver enzymes and triglycerides improved.
- Meta-analysis Curcumin cognition dose-response meta-analysis (2025) Cognitive effects require about 0.8 g a day over at least 24 weeks.
- Case report DILIN turmeric liver injury case series (2023) 10 cases, one death, with an HLA-B*35:01 association across turmeric and curcumin products.
- Review LiverTox: turmeric (2023) Likelihood score A for idiosyncratic liver injury from turmeric and curcumin.
- Review The essential medicinal chemistry of curcumin (2017) Argues curcumin is a pan-assay interference compound and chemically unstable.
- Review Curcumin umbrella review with AMSTAR-2 and GRADE assessment (2025) Most curcumin meta-analyses rated low or very low certainty.
- RCT Quercetin phytosome 200 mg/day in allergic rhinitis (2022) 66 participants, 4 weeks. Improved eye itching, sneezing, nasal discharge and sleep disturbance.
- Meta-analysis Quercetin and blood pressure, meta-analysis of 7 RCTs (2016) 587 participants. Systolic down 3.04 mmHg and diastolic 2.63 mmHg, strongest at 500 mg a day or higher.
- RCT Quercetin 730 mg/day in stage 1 hypertension (2007) 28 days. Reduced blood pressure in hypertensive participants.
- RCT Quercetin-3-glucoside 160 mg/day crossover trial (2015) 37 participants. Null on flow-mediated dilation and blood pressure.
- Meta-analysis Quercetin and human inflammation markers, meta-analysis (2020) No overall effect on CRP, IL-6 or TNF. Subgroup signals only.
- RCT Quercetin 500 mg/day and uric acid, crossover trial (2016) 22 participants. Uric acid lowered by 26.5 micromol per litre with no change in glucose or blood pressure.
- RCT Quercetin in chronic prostatitis and chronic pelvic pain syndrome (1999) 30 men, 500 mg twice daily for one month. 67% responders against 20% on placebo.
- RCT Intermittent dasatinib plus quercetin in postmenopausal women, phase 2 (2024) 60 women. Null on bone turnover overall, with an exploratory high-p16 responder signal.
- Trial Dasatinib plus quercetin in idiopathic pulmonary fibrosis, phase 1 (2023) 12 participants. Feasibility confirmed, no signal on frailty or pulmonary function.
- Trial Dasatinib plus quercetin in diabetic kidney disease (2019) 9 participants. Reduced adipose and skin senescence markers in 11 days.
- Trial Quercetin phytosome pharmacokinetics, crossover study (2019) 12 participants. Phytosome reached about 20 times the plasma concentration of plain dihydrate.
- Systematic review Human quercetin bioavailability, systematic review and meta-analysis (2025) Through July 2024. Lipid complexation and glucosylation dominate absorption.
- RCT Quercetin and upper respiratory tract infection in the community (2010) 1,002 participants. No overall benefit, with a subgroup signal in fit adults over 40.
- Trial Pravastatin exposure on quercetin 500 mg/day for 14 days (2012) Area under the curve up 24% and peak concentration up 31% through OATP1B1.
- Case report Warfarin interaction case report with quercetin (2022) Enhanced anticoagulant effect.
- RCT Quercetin and cognitive function in the community (2012) No meaningful cognitive benefit.
Glossary
Quick reference for the medical and technical terms used in this comparison.
- NF-kB Nuclear Factor kappa B
- The master switch for inflammatory gene expression. Both molecules inhibit it, which is their shared mechanism and the reason stacking adds less than expected.
- Nrf2 Nuclear factor erythroid 2-related factor 2
- The transcription factor that turns on antioxidant and detoxification genes. The second target both share.
- COX-2 Cyclooxygenase-2
- The enzyme NSAIDs block to reduce pain and inflammation. Curcumin suppresses it too, which is why it competes with diclofenac in osteoarthritis.
- CRP C-Reactive Protein
- The standard blood marker of systemic inflammation. Curcumin lowers it across more than 5,800 pooled participants. Quercetin does not.
- WOMAC Western Ontario and McMaster Universities Osteoarthritis Index
- The standard osteoarthritis pain and function score. Curcuminoids improved it by about 7 points in Feng 2022.
- Phytosome Lipid-complexed formulation
- A polyphenol bound to phospholipid to survive digestion. Quercetin phytosome reaches roughly 20 times the plasma of plain dihydrate.
- EMIQ Enzymatically Modified Isoquercitrin
- A glucosylated quercetin form that absorbs far better than rutin or plain isoquercitrin.
- Xanthine oxidase The uric acid enzyme
- The enzyme that produces uric acid, and allopurinol's target. Quercetin inhibits it, which is the mechanism behind the gout signal.
- DILIN Drug-Induced Liver Injury Network
- The US surveillance network that documented 10 turmeric liver injury cases including one death, with an HLA-B*35:01 association.
- OATP1B1 Organic Anion Transporting Polypeptide 1B1
- The liver transporter that takes up statins. Quercetin inhibits it, raising pravastatin exposure 24% in Wu 2012.
